Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03801525
Title Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination With Venetoclax in Subjects With CLL (ULTRA-V)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.

chronic lymphocytic leukemia


Ublituximab + Umbralisib + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.